Chief Executive Officer
Jim is a seasoned medical device executive, most recently serving on the management board and as Chief Patent Counsel for Boston Scientific Neuromodulation. At Boston Jim provided strategic counsel and leadership to multiple divisions and functions in product development from concept, early innovation through commercialization. Jim is a Principal of Flair, LLC, which commercializes equine health products internationally. Jim practiced IP law in Minneapolis, representing start-up through Fortune 100 companies. He has served on the board or as an advisor for early-stage companies in the fields of medical products, cyber security, animal health, biotechnology and others. He is a veterinarian and co-founder of an equine veterinary hospital.
Director of Finance and Corporate Development
Michael’s career includes experiences as founding CEO of three companies, each funded and backed by institutional investors including Intel Ventures, America Online, Bain Capital Ventures and Newspring Capital. He was formerly CEO of two health insurance companies, one which was publicly traded and more recently he was CEO of a wealth management and fintech firm based in Richmond, VA. Over the past 20 years, Ashker has developed, assisted or led financings and business model strategy and development for companies at various stages and has completed numerous capital raises for companies in multiple industries, ranging from medical devices, high-tech, software, financial tech and health food grocery.
Chief Commercial Officer
Paul Rockley is an accomplished business development, sales and marketing executive with over 25 years in the ophthalmic medical device industry. His scope of product development and commercialization experience includes surgical capital equipment, implantable & viscoelastic devices as well as OTC tears. Prior to joining Biovisics Medical, Paul held senior leadership positions in business development and global commercialization at Eyenuk, Medical Care Corp, Abbott Laboratories Vision Division, Advanced Medical Optics (AMO) and Allergan.
Paul received his Honors B.Sc. from the University of Guelph (Canada) and his MBA in Healthcare from UC, Irvine. Paul and his family live in Newport Beach, CA.
Executive Board Member
Anthony Arnold is the CEO & Founder of Precys, a company that helps investors, innovators and early stage companies advance medical innovation. Anthony has almost 25 years of experience in the development and commercialization of high-technology medical devices in neuro, orthopedics, ENT and inflammatory diseases. Prior to founding Precys, Anthony served as CEO and President for SetPoint Medical; a pioneer in the field of bioelectronic medicine where he built a world-class team that delivered a revolutionary micro-implantable platform, novel therapeutic pathway tested in multiple human trials. Prior to joining SetPoint, Anthony held leadership positions with Boston Scientific Neuromodulation, Medtronic and Smith+ Nephew. Anthony and his family live in Valencia, CA.
Medical Expert, Low Vision Optometry Advisor
Dr. Kammer is an optometrist who served as a faculty member and later in administration at Colleges of Optometry for 14 years. She holds a doctorate in Higher Education from Azusa Pacific University. She an instructor of Geometric Optics and Low Vision Rehabilitation and in 2016 began to focus her efforts on the development of endpoints for inherited retinal disease studies. Dr. Kammer also has adjunct faculty status at two universities and is currently developing a low vision department within the department of ophthalmology at University of California, Irvine. Her humanitarian work includes partnering with global charities to design and implement national clinical programs serving persons with albinism and low vision in East Africa.
Clinical & Regulatory Advisor
Barbara has 30 years of medical device industry experience in the areas of Clinical and Regulatory Affairs, with the majority of her time spent in ophthalmic device companies. Currently, Barbara serves as an independent consultant. Previously, she was Executive Director, Clinical Development Ophthalmology at Allergan. Prior to Allergan, Barbara served as VP of Clinical & Regulatory Affairs for AqueSys, Inc., which was acquired by Allergan. Prior to AqueSys, Barbara served as VP of Regulatory, Quality and Clinical Affairs at Visiogen, Inc. (acquired by Abbott) and Glaukos Corporation. Barbara obtained her BS in Biology from the University of Nevada Reno and she has an MBA from National University. Barbara is a past president of the Orange County Regulatory Affairs (OCRA) discussion group and also served as the Ophthalmic Industry Representative on the FDA’s Ophthalmic Devices Advisory Panel.
Clinical Development Advisor
Ron is the Executive Director for the Envision Research Institute (Wichita, KS). The research program at the ERI is dedicated to investigating functional implications of vision loss, access to interventions, optimizing rehabilitation therapies, and developing accessibility technology. He previously was Senior Staff / Lead Reviewer in the CDRH at FDA. His Team Lead experiences include a broad range of innovative medical device submissions (e.g., IDE, PMA, De Novo, 510(k), 513(g), Q-Sub, EFS, and EAP) He was also a member of review teams for combination products; both device and drugs as well as device and biologics. As a researcher at Stanford University he designed and executed innovative investigational studies and evaluated pharmaceutical and device therapies for adults with or aging into visual impairments. His research portfolio ranges from studies of fundamental mechanisms causing visual impairments to FDA multi-center clinical trials (including orphan indications).
Ron earned an M.S. in Physics from DePaul University and a Ph.D. in Medical Physics from the University of Chicago and a fellowship at the Wilmer Institute of the Johns Hopkins University. He is an ARVO Fellow (Association for Research in Vision and Ophthalmology) and serves on many national boards.
Contact firstname.lastname@example.org for more information.